JP7688646B2 - オーロラａ選択的阻害剤として有用な新規複素環式化合物 - Google Patents
オーロラａ選択的阻害剤として有用な新規複素環式化合物 Download PDFInfo
- Publication number
- JP7688646B2 JP7688646B2 JP2022544153A JP2022544153A JP7688646B2 JP 7688646 B2 JP7688646 B2 JP 7688646B2 JP 2022544153 A JP2022544153 A JP 2022544153A JP 2022544153 A JP2022544153 A JP 2022544153A JP 7688646 B2 JP7688646 B2 JP 7688646B2
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- alkyl
- chloro
- membered
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2020/073786 | 2020-01-22 | ||
| CN2020073786 | 2020-01-22 | ||
| CNPCT/CN2020/076159 | 2020-02-21 | ||
| CN2020076159 | 2020-02-21 | ||
| CNPCT/CN2020/085922 | 2020-04-21 | ||
| CN2020085922 | 2020-04-21 | ||
| PCT/CN2021/073169 WO2021147974A1 (en) | 2020-01-22 | 2021-01-22 | Novel heterocyclic compounds useful as aurora a selective inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023513419A JP2023513419A (ja) | 2023-03-31 |
| JP2023513419A5 JP2023513419A5 (https=) | 2024-01-25 |
| JP7688646B2 true JP7688646B2 (ja) | 2025-06-04 |
Family
ID=76993163
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022544153A Active JP7688646B2 (ja) | 2020-01-22 | 2021-01-22 | オーロラａ選択的阻害剤として有用な新規複素環式化合物 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20230128198A1 (https=) |
| EP (1) | EP4093736A4 (https=) |
| JP (1) | JP7688646B2 (https=) |
| KR (1) | KR102828343B1 (https=) |
| CN (2) | CN114423751B (https=) |
| AU (1) | AU2021209744B2 (https=) |
| CL (1) | CL2022001951A1 (https=) |
| CO (1) | CO2022010878A2 (https=) |
| IL (1) | IL294247B2 (https=) |
| MX (1) | MX2022009059A (https=) |
| PH (1) | PH12022551858A1 (https=) |
| TW (1) | TWI785474B (https=) |
| WO (1) | WO2021147974A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3823974A1 (en) | 2018-07-20 | 2021-05-26 | F. Hoffmann-La Roche AG | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
| CN112239465A (zh) | 2019-07-16 | 2021-01-19 | 微境生物医药科技(上海)有限公司 | 极光激酶抑制剂及其用途 |
| CN112898292A (zh) | 2019-12-03 | 2021-06-04 | 微境生物医药科技(上海)有限公司 | 新型极光激酶抑制剂及其用途 |
| JP2025506772A (ja) * | 2022-02-23 | 2025-03-13 | リペア セラピューティクス インコーポレイテッド | ポロ様キナーゼ４（ｐｌｋ４）阻害剤、医薬組成物、ならびにそれらを調製する方法、及びそれらの使用方法 |
| CN115057811B (zh) * | 2022-05-26 | 2024-06-14 | 安庆朗坤药业有限公司 | 一种2-溴甲基-3,5-二氟吡啶的制备方法 |
| CN115322143B (zh) * | 2022-07-21 | 2023-07-14 | 安徽德诺医药股份有限公司 | 一种4-哌啶甲酸叔丁酯盐酸盐的制备方法 |
| WO2024230647A1 (zh) * | 2023-05-05 | 2024-11-14 | 苏州信诺维医药科技股份有限公司 | 杂环类化合物、其药物组合物和其应用 |
| CN116903587B (zh) * | 2023-06-01 | 2024-03-22 | 三峡大学 | 一种角鲨烯环氧酶抑制剂及其用途 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010047602A (ja) | 2006-08-31 | 2010-03-04 | Banyu Pharmaceut Co Ltd | オーロラａ選択的阻害作用を有する新規アミノピリジン誘導体 |
| JP2011514309A (ja) | 2008-02-22 | 2011-05-06 | Ｍｓｄ株式会社 | オーロラａ選択的阻害作用を有する新規アミノピリジン誘導体 |
| WO2013129443A1 (ja) | 2012-02-29 | 2013-09-06 | 大鵬薬品工業株式会社 | 新規ピペリジン化合物又はその塩 |
| JP2016539942A (ja) | 2014-11-14 | 2016-12-22 | イーライ リリー アンド カンパニー | オーロラａキナーゼ阻害剤 |
| WO2021110009A1 (zh) | 2019-12-03 | 2021-06-10 | 微境生物医药科技(上海)有限公司 | 新型极光激酶抑制剂及其用途 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021006011A (es) * | 2018-11-30 | 2021-09-21 | Lilly Co Eli | Un inhibidor de la quinasa aurora a para su uso en el tratamiento del neuroblastoma. |
| CN112239465A (zh) * | 2019-07-16 | 2021-01-19 | 微境生物医药科技(上海)有限公司 | 极光激酶抑制剂及其用途 |
-
2021
- 2021-01-21 TW TW110102296A patent/TWI785474B/zh active
- 2021-01-22 WO PCT/CN2021/073169 patent/WO2021147974A1/en not_active Ceased
- 2021-01-22 MX MX2022009059A patent/MX2022009059A/es unknown
- 2021-01-22 CN CN202180003823.8A patent/CN114423751B/zh active Active
- 2021-01-22 CN CN202310353468.8A patent/CN116354936A/zh active Pending
- 2021-01-22 JP JP2022544153A patent/JP7688646B2/ja active Active
- 2021-01-22 AU AU2021209744A patent/AU2021209744B2/en active Active
- 2021-01-22 PH PH1/2022/551858A patent/PH12022551858A1/en unknown
- 2021-01-22 IL IL294247A patent/IL294247B2/en unknown
- 2021-01-22 US US17/794,641 patent/US20230128198A1/en not_active Abandoned
- 2021-01-22 KR KR1020227021336A patent/KR102828343B1/ko active Active
- 2021-01-22 EP EP21743926.4A patent/EP4093736A4/en active Pending
- 2021-09-24 US US17/484,456 patent/US11384066B1/en active Active
-
2022
- 2022-07-19 CL CL2022001951A patent/CL2022001951A1/es unknown
- 2022-08-02 CO CONC2022/0010878A patent/CO2022010878A2/es unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010047602A (ja) | 2006-08-31 | 2010-03-04 | Banyu Pharmaceut Co Ltd | オーロラａ選択的阻害作用を有する新規アミノピリジン誘導体 |
| JP2011514309A (ja) | 2008-02-22 | 2011-05-06 | Ｍｓｄ株式会社 | オーロラａ選択的阻害作用を有する新規アミノピリジン誘導体 |
| WO2013129443A1 (ja) | 2012-02-29 | 2013-09-06 | 大鵬薬品工業株式会社 | 新規ピペリジン化合物又はその塩 |
| JP2016539942A (ja) | 2014-11-14 | 2016-12-22 | イーライ リリー アンド カンパニー | オーロラａキナーゼ阻害剤 |
| WO2021110009A1 (zh) | 2019-12-03 | 2021-06-10 | 微境生物医药科技(上海)有限公司 | 新型极光激酶抑制剂及其用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114423751A (zh) | 2022-04-29 |
| JP2023513419A (ja) | 2023-03-31 |
| CO2022010878A2 (es) | 2022-08-19 |
| CA3161268A1 (en) | 2021-07-29 |
| CN116354936A (zh) | 2023-06-30 |
| IL294247A (en) | 2022-08-01 |
| US11384066B1 (en) | 2022-07-12 |
| KR20220131514A (ko) | 2022-09-28 |
| MX2022009059A (es) | 2022-08-15 |
| TW202140449A (zh) | 2021-11-01 |
| CL2022001951A1 (es) | 2023-04-14 |
| EP4093736A4 (en) | 2024-01-10 |
| WO2021147974A1 (en) | 2021-07-29 |
| IL294247B1 (en) | 2025-07-01 |
| IL294247B2 (en) | 2025-11-01 |
| US20230128198A1 (en) | 2023-04-27 |
| AU2021209744B2 (en) | 2023-08-31 |
| TWI785474B (zh) | 2022-12-01 |
| AU2021209744A1 (en) | 2022-07-07 |
| EP4093736A1 (en) | 2022-11-30 |
| PH12022551858A1 (en) | 2024-01-03 |
| CN114423751B (zh) | 2023-04-21 |
| KR102828343B1 (ko) | 2025-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7688646B2 (ja) | オーロラａ選択的阻害剤として有用な新規複素環式化合物 | |
| JP7644517B2 (ja) | Ｋｒａｓ突然変異型タンパク質阻害剤 | |
| EP3880676B1 (en) | 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer | |
| JP6976953B2 (ja) | Ｒｏｃｋ阻害剤としてのスピロヘプタンサリチルアミドおよび関連性化合物 | |
| US11053197B2 (en) | Carbazole derivatives | |
| EP3209652B1 (en) | Tricyclic atropisomer compounds | |
| TW202404969A (zh) | 用於治療疼痛之雜芳基化合物 | |
| TWI829481B (zh) | 雙環吲唑糖皮質素受體拮抗劑 | |
| EP2934536B1 (en) | FACTOR IXa INHIBITORS | |
| JP7168245B2 (ja) | 三環式化合物 | |
| JP2022544700A (ja) | 筋萎縮性側索硬化症および関連障害の治療のためにｔｄｐ－４３に結合する分子 | |
| CA3161268C (en) | Heterocyclic compounds useful as aurora a selective inhibitors | |
| HK40066473B (en) | Novel heterocyclic compounds useful as aurora a selective inhibitors | |
| KR20260022448A (ko) | 디히드로피리미딘-2,4(1h,3h)-디온을 함유하는 폴리시클릭 유도체 및 이의 약학적 조성물, 이의 제조 방법 및 이의 용도 | |
| HK40117760A (zh) | Rip1调节剂、其制备及用途 | |
| WO2025185736A1 (zh) | 一种多元螺环化合物的晶型、其制备方法和医药用途 | |
| HK40053093A (en) | 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer | |
| EA046797B1 (ru) | Новые гетероциклические соединения, применимые в качестве селективных ингибиторов aurora a | |
| KR20250128310A (ko) | Hur 조절 화합물 (elavl1) | |
| HK1238642A1 (en) | Carbazole derivatives | |
| HK1238642B (en) | Carbazole derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240116 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240116 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20241223 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250319 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20250424 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20250523 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7688646 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |